Current vaccine strains show high neutralization against the latest variants, but the LP.8.1 antigen may provide similar or moderately higher cross-reactive antibody response.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
Data yet to be peer-reviewed show the Omicron variant may be highly transmissible.
The neutralizing monoclonal antibody lenzilumab significantly raised survival without the use of mechanical ventilation in hospitalized COVID-19 patients and had a good safety profile, according to a phase 3 clinical trial yesterday in The Lancet Respiratory Medicine.
The case-patient traveled to South Africa and returned to the San Francisco area on Nov 22 and is isolating at home.
Delta-related COVID-19 activity showed signs of a plateau last week, the WHO says.
Severe COVID-19 may bring more than twice the risk of dying within a year.
A third dose of the Pfizer/BioNTech mRNA COVID-19 vaccine appears to counteract waning vaccine protection in the short term, according to a preliminary case-control analysis of more than 500,000 coronavirus tests in Israel.
Merck's pill is on track to be the first approved treatment for COVID-19 infections.
Also, sequencing found hints that travelers with Omicron likely contracted the virus from different people in different locations.
Those with compromised immune systems get COVID-19 after vaccination 3 times more often—but still rarely—a new study shows.
Many COVID-19 survivors experience impaired circulation, abnormal breathing patterns, and chronic fatigue syndrome an average of 9 months after diagnosis, finds a small, single-center study yesterday in JACC: Heart Failure.
